Nicholas P. Grund serves as the Senior Vice President and Chief Commercial Officer at Akebia Therapeutics Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. In his role, Grund is responsible for overseeing the company's commercial strategy and operations, including the launch and marketing of Akebia's products. His leadership is instrumental in driving the company's growth and ensuring that Akebia's therapies reach the patients who need them most. Grund brings a wealth of experience to Akebia, having spent over two decades in the pharmaceutical and biotechnology industries. Prior to joining Akebia, he held several senior leadership positions at notable companies such as Amgen, where he served as Vice President and General Manager of the Nephrology and Bone business unit. During his tenure at Amgen, Grund played a key role in the successful launch and growth of several blockbuster products, demonstrating his strategic vision and ability to navigate complex market dynamics. His deep understanding of the renal therapeutic area and proven track record in commercializing innovative treatments make him a valuable asset to Akebia's executive team. Under Grund's leadership, Akebia has made significant strides in advancing its mission to transform the lives of patients with kidney disease. He has been instrumental in the successful launch of Auryxia, Akebia's first commercial product, which is used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. Grund's strategic guidance and dedication to patient-centric innovation have positioned Akebia as a leader in the renal therapeutics space, and his continued efforts will be crucial as the company works to bring new treatments to market and improve outcomes for patients worldwide.